Shilpa Medicare receives EIR for Raichur API unit

Shilpa Medicare Limited has announced the receipt of establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at API manufacturing site located at Raichur, Karnataka, during the period between February 3 and February 7, 2020. USFDA has determined that the inspection classification of this facility is no action indicated (NAI).